Özet:

Objective: This study aimed to investigate the changes in the lipid profiles and fasting blood glucose (FBG) values of patients with prostate cancer, who underwent bilateral orchiectomy or started to use luteinizing hormone-releasing hormone (LHRH) agonists and additionally received anti-cyproterone acetate or bicalutamide, and compare these changes between alternative treatments. Materials and Methods: This retrospective study included 66 patients with complete data. Patients’ age, prostate-specific antigen values, prostate volumes, clinical stages, pathology results, type of androgen deprivation therapy, and total cholesterol (TC), low-density cholesterol, high-density cholesterol, triglyceride, and FBG values before and at 6 months after treatment were recorded. Metastatic was determined in 37 patients, whereas 26 had locally advanced and 3 had localized prostate cancer. Results: The evaluation of all patients revealed an increased FBG (p=0.010) and low-density cholesterol (p=0.012) values was significant. The comparison of patients who underwent orchiectomy and those taking LHRH agonists revealed no difference between the two groups. The difference in the TC values was statistically significant between the cyproterone acetate and bicalutamide groups (p<0.001). Conclusion: Bicalutamide significantly increases TC compared to cyproterone.

Anahtar Kelimeler: